ADVERTISEMENT

ESMO 2022 – A "new" cell therapy for metastatic melanoma

Daniela Ovadia — Agenzia Zoe   |   Conference Report   |   12 September 2022
ADVERTISEMENT

by Elena Riboldi (Agenzia Zoe)

 

Takeaway

  • Compared to ipilimumab, Tumour Infiltrating Lymphocytes (TIL) therapy reduced by 50% the chance of progression of the disease or dying from the disease in patients with metastatic melanoma.

Why this matters

  • Treatment options for patients with metastatic melanoma failing immune checkpoint inhibitors are...

          

September Challenge

Ends in 5d 16h
left
right

Topic Challenges

left
right